Turning Point Therapeutics, Inc.’s $191.5 Million Initial Public Offering

Davis Polk advised the representatives of the several underwriters in connection with a $191.5 million initial public offering of common stock of Turning Point Therapeutics, Inc.

Turning Point Therapeutics’ common stock is listed on the Nasdaq Global Select Market under the symbol “TPTX.”

Goldman Sachs & Co. LLC, SVB Leerink and Wells Fargo Securities acted as underwriters on the deal.

Turning Point Therapeutics is a clinical-stage biopharmaceutical company designing and developing novel small molecule, targeted oncology therapies to address key limitations of existing therapies and improve the lives of patients.

The Davis Polk corporate team included partner Bruce K. Dallas (Picture) and associates Lucas Tejwani and Daniel Reichert. Partner Rachel D. Kleinberg and associate Eitan Ulmer provided tax advice. Associates Daniel F. Forester and Tilak Koilvaram provided intellectual property and technology advice. Counsel Gregory D. Hughes provided executive compensation advice. Associate Matthew R. Silver provided 1940 Act advice. Counsel Marcie A. Goldstein provided FINRA advice.

Involved fees earner: Bruce Dallas – Davis Polk & Wardwell; Daniel Forester – Davis Polk & Wardwell; Marcie Goldstein – Davis Polk & Wardwell; Gregory Hughes – Davis Polk & Wardwell; Rachel Kleinberg – Davis Polk & Wardwell; Tilak Koilvaram – Davis Polk & Wardwell; Daniel Reichert – Davis Polk & Wardwell; Matthew Silver – Davis Polk & Wardwell; Lucas Tejwani – Davis Polk & Wardwell; Eitan Ulmer – Davis Polk & Wardwell;

Law Firms: Davis Polk & Wardwell;

Clients: Turning Point Therapeutics, Inc.;


Author: Ambrogio Visconti